Reference : A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malasse...
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/70402
A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent.
English
Pierard, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Ausma, Jannie [> > > >]
Henry, Frédérique mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Vroome, Valerie [> > > >]
Wouters, Luc [> > > >]
Borgers, Marcel [> > > >]
Cauwenbergh, Geert [> > > >]
Pierard, Claudine [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
2007
Dermatology : International Journal for Clinical & Investigative Dermatology
S. Karger
214
2
162-9
Yes (verified by ORBi)
International
1018-8665
1421-9832
Basel
Switzerland
[en] Administration, Oral ; Adolescent ; Adult ; Aged ; Antifungal Agents/pharmacology/therapeutic use ; Dermatitis, Seborrheic/drug therapy/microbiology ; Dose-Response Relationship, Drug ; Epidermis/microbiology/pathology ; Female ; Humans ; Imidazoles/pharmacology/therapeutic use ; Malassezia/drug effects/growth & development ; Male ; Middle Aged ; Pilot Projects ; Severity of Illness Index ; Treatment Outcome ; Triazoles/pharmacology/therapeutic use
[en] BACKGROUND: Seborrheic dermatitis is considered to be a Malassezia-driven disease. Little objective information is available so far from biometrological quantitative assessments of this skin condition. Pramiconazole is a novel triazole with potent in vitro antifungal activity, especially against Malassezia spp. OBJECTIVE: To study the sequential effects of pramiconazole on Malassezia, inflammation and epidermal changes. METHOD:This study was performed in 2 groups of subjects suffering from seborrheic dermatitis. The first group (n = 17) remained untreated and was used as control. Clinical, mycological and biometrological assessments were performed at inclusion and during the following 2 weeks. The second group of subjects (n = 10) received a single 200-mg oral dose of pramiconazole at inclusion. Clinical, mycological and biometrological evaluations were performed before and during 1 month following the single antifungal intake. For both parts of the study, several parameters were assessed including yeast density, desquamation, erythema, itching and sebum excretion. RESULTS: In the control group, no significant changes were observed in any of the parameters during the observation period. The findings were markedly different in the pramiconazole-treated subjects. The yeast density was significantly improved on days 3, 7 and 28. Desquamation, erythema, itching, and the global clinical evaluation as assessed by the patients and investigators became significantly improved on days 7 and 28. A trend in decrease of scaliness was noted. No effect on sebum excretion was evidenced. In conclusion, a single 200-mg dose of pramiconazole exhibitsin vivo efficacy in controlling some important clinical aspects of seborrheic dermatitis. Following a reduction in the number of yeasts on day 3, a decrease in the severity of clinical signs and symptoms occurred from day 7 onwards. Sebum excretion appeared uninvolved in the clearing process of seborrheic dermatitis. CONCLUSION: A single 200-mg dose of pramiconazole appears to abate seborrheic dermatitis. The density in Malassezia present on lesional skin is first decreased, followed by clearing of the clinical signs.
http://hdl.handle.net/2268/70402
10.1159/000098577
Copyright 2007 S. Karger AG, Basel.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
A PILOT STUDY.pdfPublisher postprint775.83 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.